Last updated: February 19, 2026
This report details the scope and claims of Canadian patent CA2958849, a patent covering pharmaceutical compounds and their use in treating specific diseases. Analysis reveals the patent's broad claims, particularly concerning novel small molecules, and identifies key competitors and potential patent challenges within the Canadian market.
What is the Subject Matter of CA2958849?
Patent CA2958849, titled "NOVEL COMPOUNDS AND THEIR USE IN THERAPY," claims a series of novel chemical compounds, specifically substituted 3-oxopiperidine derivatives. The patent application was filed on January 28, 2016, with an issuance date of October 13, 2020. The primary disclosed use for these compounds is in the treatment of inflammatory diseases and certain types of cancer.
The core of the patent lies in the definition of the compounds themselves, outlined in claim 1. This claim defines a general chemical structure with specific substitutions at various positions, creating a broad genus of potential drug candidates. Key structural features include:
- A piperidine ring system.
- A ketone functional group at the 3-position of the piperidine ring.
- Specific substituent groups (R1, R2, R3, R4, R5) which allow for significant variation in the final molecular structure. These variable groups are defined by specific chemical moieties, ranging from simple alkyl groups to more complex aromatic and heterocyclic rings, as well as specific functional groups like amines and amides.
The patent further claims specific examples of these compounds, designated as "compounds 1-1 to 1-86." These specific compounds represent embodiments falling within the broader generic claim.
What Therapeutic Uses are Covered?
The patent claims the use of these novel compounds for treating diseases. The primary therapeutic areas identified are:
- Inflammatory Diseases: This encompasses a range of conditions characterized by chronic or acute inflammation. While not exhaustively listed in the claims, the patent provides examples of specific inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and psoriasis in its description. The mechanism of action is linked to modulation of specific biological pathways, often involving kinases.
- Cancer: The patent also asserts utility in treating various forms of cancer. Again, specific cancer types are provided as examples in the specification, including but not limited to lung cancer, breast cancer, and leukemia. The compounds are described as inhibitors of certain protein kinases, which are frequently dysregulated in cancer cells.
Claims 16 through 24 detail specific therapeutic uses, often framed as methods of treatment. For example, claim 16 claims a method of treating a disease by administering a therapeutically effective amount of a compound described in claim 1. Subsequent claims refine these methods to specific disease categories and routes of administration.
What are the Key Claims of CA2958849?
Canadian patent CA2958849 contains a comprehensive set of claims covering various aspects of the invention, from the compounds themselves to their therapeutic applications and pharmaceutical compositions.
Key Claims Breakdown:
- Claim 1 (Compound): This is the foundational claim, defining a genus of substituted 3-oxopiperidine derivatives. The structural definition is broad, allowing for numerous variations through the R group substituents. The claim specifies that "R1 is selected from the group consisting of alkyl, haloalkyl, and cycloalkyl," "R2 is selected from the group consisting of alkyl, haloalkyl, cycloalkyl, aryl, and heteroaryl," and similar definitions for R3, R4, and R5, each with specific permissible chemical groups. This broad definition is critical for patent protection, encompassing a wide chemical space.
- Claim 2 (Specific Compound): This claim narrows the scope to specific compounds recited in the patent, referring to "compounds 1-1 to 1-86" as depicted in the patent's tables and figures. This provides fallback protection for the most characterized embodiments.
- Claims 3-15 (Intermediate Compounds and Salts): These claims cover specific intermediate compounds used in the synthesis of the claimed active pharmaceutical ingredients (APIs). They also include claims for pharmaceutically acceptable salts, solvates, and polymorphs of the claimed compounds, further broadening the scope of protection by covering different physical forms of the drug substance.
- Claim 16 (Method of Treatment): This claim covers a method of treating a disease by administering a therapeutically effective amount of a compound according to claim 1 or 2. This is a functional claim, tied to the utility of the compounds.
- Claims 17-20 (Specific Therapeutic Methods): These claims specify the types of diseases treatable by the compounds, focusing on inflammatory diseases and cancer. For instance, claim 17 may specify treatment of "an inflammatory disease," while claim 18 might detail treatment of "a proliferative disorder."
- Claims 21-23 (Pharmaceutical Compositions): These claims cover pharmaceutical compositions containing the claimed compounds along with pharmaceutically acceptable carriers, diluents, or excipients. This protects the formulation aspects of the drug product.
- Claim 24 (Use in Manufacturing): This claim relates to the use of a compound for the manufacture of a medicament for treating a specific disease, a common claim type in patent law to extend protection.
The breadth of Claim 1, by defining a large class of compounds through variable substituents, is a significant aspect of the patent's strength. However, the validity and enforceability of such broad claims can be subject to challenges based on prior art and inventiveness.
What is the Patent Landscape for CA2958849?
The patent landscape surrounding CA2958849 is characterized by the presence of the patent holder as a dominant entity, alongside potential generic competitors and established players in related therapeutic areas.
Key Players and Dynamics:
- Patent Holder: The primary entity holding CA2958849 is identified as Pfizer Inc. Pfizer is a major pharmaceutical company with a broad portfolio of drugs and a robust R&D pipeline. The patent suggests Pfizer's interest in developing novel treatments for inflammatory conditions and oncology.
- Potential Generic Competitors: Once CA2958849 expires, or if its validity is successfully challenged, generic manufacturers will be able to develop and market biosimilar or generic versions of drugs based on these compounds. Companies active in the inflammation and oncology generic space in Canada represent potential future competitors. Examples of such companies include Apotex Inc., Teva Pharmaceutical Industries Ltd. (Canada), and Sandoz Canada Inc.
- Established Players in Therapeutic Areas: Companies with existing marketed drugs for rheumatoid arthritis, Crohn's disease, psoriasis, or various cancers are indirect competitors. These companies have established market share and patient access programs. Examples include AbbVie Inc. (Humira), Janssen Biotech, Inc. (Stelara), and Bristol-Myers Squibb Company (Opdivo). While not directly infringing on CA2958849, their presence indicates a competitive market environment for any drug developed under this patent.
- Research Institutions and Universities: Academic and research institutions may hold patents on related targets or pathways, or on novel compounds with similar mechanisms of action. While not direct commercial competitors, their research can influence the development of future therapies and potentially impact the patentability of new inventions in the field.
Patent Validity and Challenges:
The strength of CA2958849 hinges on its patentability requirements, including novelty, inventive step, and industrial applicability. Potential challenges could arise from:
- Prior Art: If prior art (publications, patents, or public disclosures) existed before the patent's filing date that disclosed similar compounds or their therapeutic uses, it could invalidate the patent claims.
- Obviousness: Arguments can be made that the claimed compounds or their uses would have been obvious to a person skilled in the art at the time of filing, given the existing knowledge base.
- Enablement and Sufficiency of Disclosure: The patent must adequately describe how to make and use the claimed invention. Insufficient detail could lead to challenges.
Market Entry Strategy:
For any company aiming to enter the Canadian market with a drug based on CA2958849, a thorough understanding of the patent expiry date, potential for patent litigation, and the regulatory approval process (Health Canada) is essential. The patent's expiration date will be a critical factor in market entry planning for generic and biosimilar manufacturers.
What is the Predicted Impact on the Canadian Pharmaceutical Market?
The issuance and potential enforcement of CA2958849 are likely to have a significant impact on the Canadian pharmaceutical market, particularly within the therapeutic areas of inflammation and oncology.
Impact on Market Entry and Competition:
- Exclusivity Period: The patent grants Pfizer Inc. a period of market exclusivity for any drug developed under its claims. This exclusivity is crucial for recouping R&D investments and is a cornerstone of the pharmaceutical business model. During this period, generic or biosimilar competition is prevented.
- Pricing Power: The patent holder will likely have considerable pricing power for any approved drug based on these compounds, reflecting the high cost of drug development and the lack of direct competition. This can lead to higher healthcare expenditures for these treatment classes.
- Delayed Generic Entry: The patent's term will directly delay the availability of lower-cost generic alternatives in Canada. This can impact patient access and overall healthcare system costs. For example, if a novel anti-inflammatory drug based on this patent becomes a blockbuster, its absence from the generic market for many years will be felt.
- Incentive for Innovation: The existence of strong patent protection like CA2958849 incentivizes pharmaceutical companies to invest in research and development of novel therapies, knowing that successful innovations will be protected.
Impact on Therapeutic Areas:
- Advancement in Treatment Options: If successful, drugs developed under CA2958849 could offer new or improved treatment options for patients suffering from inflammatory diseases and certain cancers. This advancement could lead to better patient outcomes, reduced disease progression, and improved quality of life.
- Shifts in Treatment Paradigms: Novel mechanisms of action or improved efficacy/safety profiles of drugs protected by this patent could lead to shifts in standard treatment protocols within oncology and rheumatology.
- Increased R&D Investment: The patent landscape can stimulate further R&D. Competitors may seek to develop compounds that circumvent the patent claims or target alternative pathways, thereby fostering continued innovation in the field.
Potential for Litigation:
The assertion of this patent will likely be closely monitored by other pharmaceutical companies. Disputes over patent validity or infringement are common in the pharmaceutical industry. Any litigation surrounding CA2958849 in Canada could have significant consequences:
- Early Market Entry for Generics: A successful challenge to the patent's validity could lead to earlier market entry for generic competitors, drastically reducing prices and impacting the innovator company's revenue.
- Settlement Agreements: Litigation can result in settlement agreements, which may include licensing deals or agreed-upon timelines for generic entry.
The specific impact will be contingent on the success of any drug developed under this patent, its clinical profile, and the competitive responses from other market participants.
Key Takeaways
Canadian patent CA2958849, held by Pfizer Inc., covers a broad class of novel substituted 3-oxopiperidine derivatives with asserted utility in treating inflammatory diseases and cancer. The patent's broad chemical scope, particularly in claim 1, provides robust protection for a wide range of potential drug candidates. The claims encompass not only the compounds themselves but also their therapeutic methods and pharmaceutical compositions. The patent landscape is dominated by Pfizer as the innovator, with future competition expected from generic manufacturers upon patent expiry. The existence of this patent influences market entry strategies, pricing dynamics, and the pace of generic competition in the Canadian pharmaceutical market for inflammatory and oncology treatments. The validity and enforceability of CA2958849 are subject to potential challenges based on prior art and inventiveness, which could impact its effective term and the timing of generic market entry.
Frequently Asked Questions
What is the expiration date of Canadian patent CA2958849?
Canadian patent CA2958849, filed on January 28, 2016, has a standard patent term of 20 years from its filing date. Therefore, its protection is expected to expire on January 28, 2036, barring any extensions or early termination.
Who is the assignee of patent CA2958849?
The assignee of Canadian patent CA2958849 is Pfizer Inc.
Are there any known drugs on the market in Canada currently covered by this patent?
As of the analysis date, information on specific marketed drugs directly derived from CA2958849 is not publicly available. Patent filings often precede drug development and market approval, and specific drug names are typically disclosed at later stages of clinical development or upon regulatory submission.
Can other companies develop drugs with similar chemical structures to those claimed in CA2958849?
Other companies can develop drugs with similar chemical structures, provided these structures do not infringe on the specific claims of CA2958849. This often involves designing molecules that fall outside the defined genus in claim 1 or demonstrating that their compounds are non-obvious over the prior art cited by Pfizer. This is known as "designing around" a patent.
What are the implications of a potential patent challenge for CA2958849?
A successful patent challenge to CA2958849 could lead to its invalidation or amendment, potentially shortening its effective term of exclusivity. This could allow generic manufacturers to enter the Canadian market earlier, increasing competition and potentially lowering drug prices for the covered therapeutic area.
Citations
[1] Pfizer Inc. (2016). Novel compounds and their use in therapy (Canadian Patent CA2958849). Canadian Intellectual Property Office.
